Browsing Tag
EYLEA HD
1 post
EYLEA HD and DUPIXENT anchor Regeneron’s 2026 growth plan amid clinical pipeline acceleration
Find out how Regeneron’s 18 new Phase III trials and four FDA approval targets in 2026 aim to reshape growth beyond DUPIXENT and EYLEA. Read the full story.